Welcome to our dedicated page for Brainsway news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway stock.
BrainsWay Ltd. reports developments in noninvasive neurostimulation treatments for mental health disorders. The company markets its proprietary Deep TMS platform, with FDA-cleared indications that include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and derives revenue from leases and sales of Deep TMS systems.
Recurring updates include financial results, operating guidance, system placements, reimbursement and payer coverage for TMS therapy, clinical data for Deep TMS protocols such as SWIFT, and additional regulatory clearances. Company news also covers strategic minority-stake and milestone-based investments in mental health providers and related neurostimulation technologies, along with investor conference participation and operational updates across its U.S. and Israel-based business.
BrainsWay Ltd. (NASDAQ: BWAY) will announce its Q2 2020 financial results on August 12, 2020, before U.S. markets open. A conference call will take place at 8:30 AM ET to discuss the results and business updates. BrainsWay specializes in non-invasive treatments for brain disorders through its Deep TMS technology, which has FDA approval for treating major depressive disorder and obsessive-compulsive disorder. The company is currently conducting clinical trials for various neurological and psychiatric disorders. Forward-looking statements involve risks and uncertainties.